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Abstract 
Objective:  Stearoyl Co-A desaturase (SCD-1), the rate limiting enzyme in 
monounsaturated fatty acid synthesis, is critical for lipid synthesis, lipid oxidation 
and possibly type 2 diabetes. This study characterized SCD-1 activity through 
fatty acids ratios in baseline plasma measurements and established their 
association with incident diabetes in the Atherosclerosis Risk in Communities 
(ARIC) study.   
Research Design & Methods: In 2782 Caucasian adults (age 45-64, 47% men) 
free of diabetes, baseline SCD-1 activity was approximated by plasma fatty acid 
ratios in cholesterol esters (SCD16c-16:1/16, SCD18c-18:1/18:0) and plasma 
phospholipids (SCD16p-16:1/16:0, SCD18p-18:1/18:0). Incident diabetes was 
ascertained during three follow up visits. The relationship between SCD-1 activity 
and incident diabetes was evaluated by Cox proportional hazards regression. 
Results: During follow-up, 208 (7.5%) participants developed diabetes (mean 8 
years ± SD 2.1 years). The various SCD-1 ratios correlated with each other 
(p<0.001). After adjusting for age and gender, higher levels of SCD16c and 
SCD16p were positively associated with incident diabetes. Higher levels of 
SCD18p were inversely associated with incident diabetes. After additional 
adjustment for parental history of diabetes, smoking, blood pressure, activity, 
carbohydrate intake, fiber intake, saturated fat intake, Waist-hip ratio, education, 
alcohol, and body-mass-index (BMI), only SCD16c remained positively 
associated with incident diabetes (RR=1.1:  95%CI 1.01-1.30 ; p=0.03).  
ii 
  
This association disappeared with additional adjustment for insulin resistance. 
Conclusions:  Approximation of SCD-1 activity by SCD16c was positively 
associated with incident diabetes but this association was weak, especially when 
considering common phenotypic measures (i.e. BMI and Waist-hip ratio). 
Measurements of SCD-1 activity should be further refined.   
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 Given the epidemic of Type 2 diabetes, there is much interest in 
biomarkers, particularly serum fatty acids, in predicting incident diabetes. 
Previously, epidemiologic data from the Atherosclerosis Risk in Communities 
(ARIC) cohort demonstrated a positive association between incident diabetes 
and fasting plasma free fatty acid levels (1) as well as the proportion of saturated 
fatty acid in plasma (2).  
 The composition of plasma fatty acids depends on many factors, including  
fatty acid intake (3), age, gender, exercise, endogenous synthesis and genetic 
predisposition (4). In particular, the role of Stearoyl Co-A desaturase (SCD-1), 
the rate limiting enzyme in monounsaturated fatty acid synthesis and a critical 
player in lipid synthesis and oxidation, needs to be considered. SCD-1, a delta9 
desaturase, introduces a double bond at the c-9 location, with preferred 
substrates being palmitoyl (16:0) and stearoyl CoA (18:0) (5).  
 This enzyme is found in many lipogenic tissues, specifically the liver (6), 
adipose tissue (6) and muscle (7). SCD-1 deficiency improves insulin sensitivity 
likely due to increased lipid oxidation (8), improved skeletal muscle insulin 
signaling (9) and enhanced hepatic AMP-Kinase activity (10). Inhibition of SCD-1 
activity may be a potential mechanism for treatment of obesity and diabetes (11). 
Recent studies inhibiting SCD-1 expression in vivo by antisense oligonucleotide 
injection prevented diet induced obesity in mice (12) and specifically improved 
hepatic insulin resistance in rats and mice (13). 
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 Many approximations of SCD-1 desaturase activity, using the 
product/precursor ratio in plasma, exist (14-18). One of the earliest studies, using 
a mouse model with a targeted SCD-1 knockout and a mouse model with 
naturally occurring SCD-1 deficiency, showed the palmitoleate/palmitate 
(16:1/16:0) and oleate/stearate (18:1/18:0) ratio in plasma was proportional to 
SCD-1 gene dosage (14). Further evidence recommended against approximating 
SCD-1 activity in whole plasma due to heterogeneity in plasma lipid 
subcomponents: free fatty acids, cholesterol esters, phospholipids, and 
triglycerides (4; 19).  As fasting cholesterol esters, triglycerides, and 
phospholipids are primarily derived from the liver, the approximation of SCD-1 
activity by the product/substrate ratio in plasma cholesterol esters and plasma 
phospholipids has been attributed to hepatic SCD-1 activity (15). 
 Although epidemiological studies have demonstrated that higher levels of  
SCD-1 activity was associated with the metabolic syndrome (16), insulin 
resistance (17) (18) and diabetes (20), a prospective cohort study describing the 
association between baseline SCD-1 activity and incident diabetes has not yet 
been published. The goal of this study was to use a large, prospective cohort, the 
Atherosclerosis Risk in Communities Study (ARIC), to evaluate SCD-1 activity 
through the precursor-product ratio (16:1/16:0, 18:1/18:0) in cholesterol esters 
and plasma phospholipids as a biomarker for incident diabetes. The hypothesis 
was that higher levels of SCD-1 activity would be associated with higher risk of 
incident diabetes.  
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Subjects: 
 The Atherosclerosis Risk in Communities Study (ARIC) is a population 
based cohort study of 15792 participants (ages 45-64 years) enrolled from 4 
communities (Forsyth County NC, Jackson MS, Minneapolis MN, Washington 
County MD) during 1987-1989 with follow-up exams approximately 3 years apart 
(1990-1992, 1993-1995, 1996-1998) (21). This study was restricted to 
participants (n=4009) from the Minneapolis field center, which is the only center 
with measurement of plasma fatty acid composition from phospholipid and 
cholesterol esters. Plasma was collected and stored at baseline and 
subsequently analyzed for fatty acid composition 2 years after the initial 
collection. The ARIC study was approved by the Institutional Review Board (IRB) 
of each participating center. The current study was specifically approved by the 
IRB at the University of Minnesota. 
 Of the participants in the Minneapolis cohort, 37 subjects were nonwhite 
and excluded from the analysis (due to small numbers). Of the remaining 3972 
subjects, an additional 1190 participants were excluded because they had one or 
more of the following at baseline: prevalent or unknown diabetes status (n=432), 
missing fatty acid measurements (n=37) and use of medications (lipid lowering 
agents and bile acid sequestrants) which may affect the lipid profile (n=906 total 
subjects, n=721 subjects not previously excluded). After the applying the 
exclusion criteria, 2782 participants were available for analysis. 
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Plasma Fatty Acid Measurement:  
 Plasma collection and fatty acid composition measurements have been 
previously described (2; 3). Briefly, fasting blood was collected in EDTA, 
centrifuged and frozen at -70 degrees Celsius until analysis approximately 2 
years later. The lipid extract was obtained by exposing plasma to methanol and 
chloroform under a nitrogen atmosphere. The cholesterol ester and phospholipid 
fractions were separated using a silica gel plate (Silica Gel H: Analtech, Newark 
DE) and two stage mobile phase development with 80:20:1 (by vol) and 40:60:1 
(by vol) solvents of petroleum ether, diethyl ether, and glacial acetic acid. 
Dichlorofluorescein was used to visualize the phospholipid, cholesterol ester, 
triacylglycerol, and free fatty acid bands under UV light. The phospholipid and 
cholesterol esters were scraped into separate test tubes and converted into 
methyl esters of fatty acids by boron trifluoride catalysis (22). The methyl esters 
were separated and measured using gas chromatography (model 5890 Hewlett 
Packard, Avondale, PA) equipped with a glass capillary column (J&W Scientific, 
Folsom CA) and a flame ionization detector. Each fatty acid peak was identified 
by comparison to synthetic standards of known fatty acid composition. The 
relative amount was quantified by integrating the area under the specific peak 
and dividing the results by the total area for all fatty acids. Short term (reliability 
coefficient: 0.5 to 0.93 for plasma cholesterol esters, 0.31 to 0.89 for plasma 
phospholipids) and long term repeatability (reliability coefficient: 0.35 to 0.83 for 
plasma cholesterol esters, 0.30 to 0.81 for plasma phospholipids) of this 
technique in quantifying fatty acid composition has been previously reported (23). 
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 Given the precedent set by previous epidemiological studies (16-18), 
plasma fatty acid composition from phospholipid and cholesterol esters was used 
as a surrogate measure of  SCD-1 activity. As these samples were obtained in a 
fasting state, the assumption is that the measured SCD-1 activity primarily 
represents hepatic SCD-1 activity (15). Given that SCD-1 converts 16:0 to 16:1 
and 18:0 to 18:1, SCD-1 activity was approximated by 4 different measures: 
16:1/16:0 in plasma cholesterol esters (SCD16c), 16:1/16:0 in plasma 
phospholipids (SCD16p), 18:1/18:0 in plasma cholesterol esters (SCD18c) and 
18:1/18:0 in plasma phospholipids (SCD18p). 
Primary Outcomes:  
 Incident diabetes was defined by one or more of the following: self-
reported physician diagnosis, fasting (≥ 8 hours) serum glucose greater than or 
equal to 7.0 mmol/l (126 mg/dL), non-fasting serum glucose greater than or equal 
to 11.1 mmol/l (200 mg/dL), or use of anti-diabetes medication within the past 
two weeks, at any of the three follow up visits for the ARIC study. The date of 
diabetes incidence was estimated by linear interpolation using glucose values at 
the ascertaining visit and the previous one, as previously described (24). 
Other Measurements: 
 The covariates in the analysis were measured at baseline and included : 
age, gender, smoking history (cigarette-years), education level, alcohol use, 
parental history of diabetes, body mass index (BMI), dietary fiber intake, dietary 
carbohydrate intake, dietary saturated fat intake, and blood pressure (25). These 
covariates were selected as possible confounders due to their association with 
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altering the plasma lipid profile (cigarette smoking (26), dietary fiber intake (4),  
dietary carbohydrate intake (6), saturated fat intake (4), alcohol use (27)) and 
association with incident diabetes (parental history of diabetes, physical activity, 
education, waist-hip ratio, BMI, HOMA-IR, hypertension) (28). Trained 
interviewers collected information on alcohol intake and dietary intake using an 
adaptation of Willett’s food frequency questionnaire (29). Insulin and glucose 
were measured as previously reported (30). Insulin resistance was represented 
by the homeostatic model assessment (HOMA-IR) (31). Physical activity 
information at baseline was assessed by the Baecke questionnaire (32) and 
summarized quantitatively as total activity (work, leisure, and sport activity: range 
3-15) and play activity (leisure and sport activity: range 2-10). Adjustment of 
cigarette smoking including consideration of both smoking history and smoking 
years, but as this did not change the results in a sensitivity analysis,  smoking 
years was used in the final model. 
Statistical analysis:  
 All analysis was conducted using SAS (version 9.2 - SAS institute, Inc, 
Cary, North Carolina). Baseline characteristics were summarized for those with 
and without incident diabetes and compared using two-sample t-tests. The chi-
squared test was used for categorical outcomes. Pearson’s correlation 
coefficients were computed between the different SCD-1 ratios.  
 After confirming the Cox proportional hazards assumption, the 
proportional hazards model was used to evaluate the association of the SCD-1 
ratio with incident diabetes, adjusting for covariates of interest. Model 1 adjusted 
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for age and gender. Model 2 additionally adjusted model 1 for other risk factors, 
specifically parental history of diabetes (absent/present), cigarette smoking 
(cigarette years), mean arterial pressure (mmHg), physical activity (total of work, 
leisure and sport activity), dietary fiber intake (grams/day), carbohydrate intake 
(% of total kcal), saturated fat intake (% of total kcal), alcohol use (grams/day), 
education (<high school, high school, > high school), waist-hip ratio, and BMI 
(kg/m2). The third model additionally adjusted model 2 for insulin resistance 
(HOMA-IR). Differences in risk factors between groups (ie participants 
with/without incident diabetes, extreme quintiles of SCD-1) were measured using 
a two way unpaired T-test. Statistical significance was set at p<0.05 for all 
analyses.  
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Demographics: 
 Among the 2782 subjects (47% men, n=1317), 208 (7.5%) participants 
developed diabetes over a mean of 8 years (± SD 2.1 years) of follow-up. 
Compared to subjects without diabetes, subjects who developed incident 
diabetes had the following variables significantly higher at baseline:  BMI, Waist-
hip ratio, fasting glucose, HOMA-IR, mean arterial pressure, dietary fiber intake, 
and SCD16c ratio. Subjects who developed incident diabetes were more likely to 
be men and have a parental history of diabetes, higher smoking exposure, and 
lower educational level (Table 1).  Compared to subjects without diabetes, 
subjects who developed incident diabetes had lower levels of play activity (as 
measured by a combination of sport and leisure) and lower SCD18p ratio at 
baseline. Baseline saturated fat intake, alcohol intake, carbohydrate intake, total 
activity, age, SCD16p and SCD18c ratios were not different.   
Correlation between SCD1 ratios: 
 The different SCD-1 ratios were positively and significantly correlated with 
each other (all p<0.001). Correlations with SCD16c were 0.78 (SCD16p), 0.66 
(SCD18c) and 0.55 (SCD18p). Correlations with SCD16p were 0.48 (SCD18c) 
and 0.58 (SCD18p). Correlation of SCD18c with SCD18p was 0.64. 
Correlation between SCD1 ratios and Baseline Risk Factors for Diabetes 
 The different approximations of SCD-1 (SCD16c, SCD16p, SCD18c, 
SCD18p) correlated with known risk factors for diabetes, especially insulin 
resistance (HOMA-IR), BMI, and Waist-hip ratio.   HOMA-IR was positively 
Page 12 of 38 
 
correlated with SCD16c (0.1) and SCD16p (0.06) and negatively correlated with 
SCD18c (-0.17) and SCD18p (-0.24) (all p<0.01). BMI was positively correlated 
with SCD16c (0.12) and SCD16p (0.06) and negatively correlated with SCD18c 
(-0.16) and SCD18p (-0.22) (all p<0.01). Waist-hip ratio positively correlated with 
SCD16c (0.08) and negatively correlated with SCD18c (-0.14) and SCD18p (-
0.11) (all p<0.01). The Waist-hip ratio was not correlated with SCD16p (-0.02 : p 
= 0.22),   
Baseline risk factors by quintiles of SCD16C ratio: 
 Given the association between quintiles of SCD16 ratio and incident 
diabetes, differences in baseline risk factors between the lowest and highest 
quintiles of SCD16c were examined. For SCD16c (Table 2), the highest quintile 
of SCD16c was associated with higher age, alcohol intake, BMI, Waist-hip ratio, 
Mean Arterial Pressure, fasting glucose, and HOMA-IR. The participants with the 
highest quintile of SCD16c had a lower percentage of men, lower education 
level, and higher rates of smoking. The participants in the highest quintile of 
SCD16c had lower dietary fiber intake, carbohydrate intake, and activity. Family 
history of diabetes and dietary saturated fat intake were not different between the 
extreme quintiles of SCD16c. Similar findings were observed between SCD16p 
(data not shown) and SCD16c with the exception of the following: carbohydrate 
intake (no difference between extreme quintiles of SCD16p), saturated fat intake 
(no difference between extreme quintiles of SCD16p), dietary fiber intake (no 
difference between extreme quintiles of SCD16p), fasting glucose (no difference 
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between extreme quintiles of SCD16p), and Waist-hip ratio (no difference 
between extreme quintiles of SCD16p).  
 The differences in baseline risk factors between the lowest and highest 
quintiles of SCD18p were also examined. For SCD18p (Table 3), the highest 
quintile of SCD18p was associated with higher smoking history, higher saturated 
fat intake and higher alcohol intake. The highest quintile of SCD18p was 
associated with lower percentage of men, education, carbohydrate intake, fiber 
intake, BMI, Waist-hip ratio, glucose and HOMA. There was no difference in age, 
parental history of diabetes, activity level, or mean arterial pressure between the 
extreme quintiles. 
Association between SCD1 ratios and Incident Diabetes  
 The associations of SCD-1 quintiles with incident diabetes were examined 
for each SCD-1 ratio separately. In Model 1 (age and gender adjusted), there 
was a significant positive association between SCD-1 quintiles and incident 
diabetes for both SCD16c and SCD16p. In contrast, there was a significant 
negative association between SCD18p quintiles and incident diabetes (Figure 1). 
The associations of SCD16c quintiles and incident diabetes persisted when 
adjusting for additional risk factors (Model 2), but disappeared when additionally 
adjusting for HOMA-IR (Model 3). The association between SCD16p quintiles 
and SCD18p quintiles with incident diabetes disappeared when other risk factors 
(Model 2, Model 3) were considered.   
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 To our knowledge, this is the first study examining SCD-1 activity, as 
represented by various plasma fatty acid ratios (SCD16c, SCD16p, SCD18c, 
SCD18p) and the associations with incident diabetes in a prospective cohort of 
men and women.  This study complemented previous epidemiologic data from 
the Atherosclerosis Risk in Communities (ARIC) cohort which showed a positive 
association between incident diabetes and fasting plasma free fatty acid levels 
(1) as well as the proportion saturated fatty acid composition in plasma (2). The 
approximations of SCD-1 activity (SCD16c, SCD16p, SCD18c, SCD18p) were 
moderately to highly correlated with each other.  However, SCD16c and SCD16p 
were positively associated with typical risk factors for incident diabetes (BMI, 
HOMA-IR, Waist-hip ratio) whereas SCD18c and SCD18p were inversely 
associated with these risk factors. The approximation of SCD-1 activity by 
SCD16c (16:1/16:0 ratio in plasma cholesterol esters) had the strongest 
association with incident diabetes. However, the association between SCD16c 
and incident diabetes was attenuated when considering further risk factors for 
type 2 diabetes (i.e. BMI and Waist-hip ratio) and was absent when considering 
insulin resistance (HOMA-IR). 
 Although novel in its measure of incident diabetes in a prospective cohort 
of women and men, the ARIC study generally agrees with previous literature. 
SCD-1 activity, as approximated by SCD16c, has been associated with reduced 
insulin sensitivity (17) and the metabolic syndrome (16). These previous studies 
(16; 17), however, were limited to men and examined the association between 
baseline levels of SCD16c and insulin sensitivity (as measured by the 
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hyperinsulinemic, euglycemic clamp) or metabolic syndrome (16) twenty years 
later. Despite the independent association between SCD16c and insulin 
sensitivity when adjusting for additional risk factors (i.e. BMI, glucose, diastolic 
blood pressure, triglycerides, HDL, physical activity, smoking, socioeconomic 
status, insulin, saturated fat intake), the strongest predictor of insulin sensitivity 
remained BMI (17). Likewise, the association between SCD16c and development 
of the metabolic syndrome disappeared when adjusting for BMI or physical 
activity (16).  
 When examining SCD-1 activity as approximated by the different plasma 
phospholipids (SCD16p, SCD18p) and the predictive value of incident diabetes, 
the results for SCD16p, but not SCD18p, were consistent with Patel et al. (20). 
Using a smaller (cases:n=199, control:n=184)) case-control study with narrower 
criteria (no laboratory assessment) for the diagnosis of diabetes, Patel et al, 
reported a positive association between SCD1 activity (as measured by SCD16p 
or SCD18p) and incident diabetes (20). The difference in SCD18p and incident 
diabetes in the Patel versus the current ARIC study may be explained by several 
factors. The current ARIC study is a larger prospective study (n=2782) with 
broader inclusion criteria (including laboratory assessment) for diabetes (24). 
Although the duration of follow-up (~8 years) was comparable, the current ARIC 
study enrolled a younger population (mean age 53) compared with the Patel et.al 
study (mean age 64) (20). The current ARIC study reported an association 
between dietary saturated fat intake and SCD18p quintiles but no association 
between dietary saturated fat intake and quintiles of SCD16c or SCD16p. In the 
Page 17 of 38 
 
ARIC cohort, the contribution of oleate (18:1 comprises 12% of total energy) to 
the diet was higher than palmitate (16:0 comprises 6.9% of total energy) (3), 
which may potentially alter plasma fatty acid levels of 18:1 (4) as indicated by the 
low reliability coefficient (0.39)  for 18:1 observed in plasma phospholipids (23). 
 Although our study showed that measures of SCD-1 activity may be 
independently associated with incident diabetes and risk factors for type 2, this 
association was weak, especially when compared to common phenotypic 
measures (i.e. BMI and Waist-hip ratio) and were attenuated after further 
adjustment for risk factors. SCD-1 activity may be associated with incident 
diabetes in several ways. SCD-1 deficient mice have reduced body fat, increased 
insulin sensitivity and are protected from the metabolic effects of a high fat diet 
(8). This effect appears to be due to increased lipid oxidation (8), reduced lipid 
synthesis (8), and enhanced insulin signaling in the muscle, white adipose tissue, 
liver, and heart (33). Alternatively, one of the products of SCD-1 activity, 
palmitoleic acid (16:1) may play a role in incident diabetes, although the details 
remain unclear. Diabetes has been associated with high levels of palmitoleic acid 
(16:1) in serum free fatty acids (34), plasma/serum cholesterol esters (2) and 
plasma phospholipids (35).    
 The resources of the ARIC study were uniquely suited to examine the 
association between SCD-1 activity and incident diabetes. The correlation 
between dietary fat composition, as measured by the food frequency 
questionnaire and plasma fatty acid composition has been previously published 
(3). Baseline measures of diet, activity, plasma free fatty acid, and plasma fatty 
Page 18 of 38 
 
acid composition were available for a proportion of study participants, with  
previously described associations between fasting plasma free fatty acid (1) and 
proportion of plasma saturated fatty acid (2) with incident diabetes. The use of an 
older cohort (age group 45-64 at baseline) with 8 years of follow up ensured a 
reasonable event rate of incident diabetes. Finally, the diagnosis of diabetes was 
confirmed through glucose measures rather than strictly by self-report. However, 
as previously published, the timing of the onset of diabetes was uncertain and 
ascertained by interpolation between visits (1; 24).   
  Our study was novel in its assessment of multiple approximations of 
SCD-1 activity (SCD16c, SCD16p, SCD18c, SCD18p ratios) and evaluation of 
these ratios relative to incident diabetes in the setting of long term, prospective 
follow-up. The values for SCD16c obtained in this study were comparable to 
those previously reported in studies using the 16:1/16:0 ratio in cholesterol esters 
(0.33±SD 0.09) (16; 17). The values of SCD16p and SCD18p were also 
comparable to previous literature using the 16:1/16:0 ratio or 18:1/18:0 ratio in 
plasma phospholipids to approximate SCD-1 activity (20).   
 A limitation of the study, but not unique to the current study, was the use 
of the plasma product-precursor ratio for SCD-1 in approximating SCD-1 activity. 
The ratio of 16:1/16:0 measured in serum has been shown to correlate with the 
16:1/16:0 ratio in hepatic tissue (36). The 16:1/16:0 ratio in hepatic tissue has 
been shown to reflect hepatic SCD-1 mRNA (37). In the setting of a stable diet, 
plasma fatty acid variation was highest for 16:1 in cholesterol esters, suggesting 
that alterations in 16:1 levels in plasma may be due to desaturase activity (38). 
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However, dietary intake, alcohol intake, smoking, physical activity, and 
medication may influence fatty acid composition (4), with varying effects 
depending on the specific lipid (3). Analytical variation may affect reproducibility, 
obscuring changes in SCD16p due to low levels of 16:1 in plasma phospholipids 
(approximate 1% molar %) compared with plasma cholesterol esters (5% molar 
%) (4). Another limitation of the study is the one-time baseline measurement of 
plasma fatty acid composition, which does not incorporate time-dependent 
variation in SCD-1 activity/plasma fatty acid composition.  Lastly, due to 
increased lipolysis, free fatty acid levels are approximately twice as high in 
humans with insulin resistance (39), and type 2 diabetes (40) compared with 
normal humans. Whether the increased free fatty acid levels affect plasma 
phospholipid composition and plasma cholesterol ester composition remains 
unknown; nevertheless, the association between increased free fatty acids and 
reduced insulin sensitivity may confound the reported findings.   
 Using a prospective cohort to examine the relationship between SCD-1 
and incident diabetes, this study found that the approximation of SCD-1 activity 
by the 16:1/16:0 ratio in plasma cholesterol esters had the strongest association 
with incident diabetes. However, this association remained weak, especially 
when compared to more easily accessible phenotypic measures such as BMI 
and Waist-hip ratio and was substantially attenuated when adjusting for 
additional risk factors (parental history of diabetes, cigarette smoking, mean 
arterial pressure, physical activity, dietary fiber, saturated fat intake, alcohol use, 
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education, Waist-hip ratio, BMI, HOMA-IR).  Further refinement of measurements 
for SCD-1 activity is recommended.   
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Table 1: Baseline characteristics of participants with and without incident 
diabetes   
No diabetes (n=2574) Incident Diabetes (n=208) P value 
Age  (years) 53.3 (0.1) 53.6 (0.4) 0.4
Gender (male) 45.9% 65.4% <0.01
Education (<high school) 5.0% 9.2% 0.04
Positive Parental History of diabetes (%) 18.8% 29.8% <0.01
Positive hx of smoking (%) 60.9% 72.9% <0.01
Cigarette Years Smoked 303.7 (7.5) 416.7 (29) <0.01
Diet-fiber intake (grams) 16.1 (0.1) 17.1 (0.6) 0.04
Diet Saturated fat intake (%kcal) 12.6 (0.1) 12.6 (0.2) 0.9
Diet-Carbohydrate intake (%kcal) 46.4 (0.2) 45.6 (0.6) 0.2
Alcohol intake (g/day) 8.2 (0.3) 9.3 (1.1) 0.3
Total Activity [3 (low) to 15 (high)] 7.4 (0.03) 7.3 (0.1) 0.4
Sport+Leisure Activity [2 (low) to 10 (high)] 5.2 (0.02) 5.0 (0.08) <0.01
BMI (kg/m2) 26.1(0.1) 30.4 (0.3) <0.01
Waist hip ratio 0.9 (0.002) 1.0 (0.005) <0.01
Mean Arterial Pressure (mmHg) 87.1 (0.2) 92.7 (0.7) <0.01
Fasting glucose (mmol/l) 5.4 (0.01) 6.0 (003) <0.01
HOMA-IR 2.1 (0.03) 4.1 (0.2) <0.01
SCD16c   0.2 (0.002) 0.3 (0.007) <0.01
SCD16p 0.02 (0.0001) 0.03 (0.0004) 0.1
SCD18c 18.5 (0.1) 17.8 (0.2) 0.2
SCD18p 0.7(0.002) 0.6 (0.008) <0.01  
Results reported as mean (Standard Error) 
 SCD16c represents 16:1/16:0 in plasma cholesterol esters.  
 SCD16p represents 16:1/16:0 in plasma phospholipids.  
 SCD18c represents 18:1/18:0 in plasma cholesterol esters.  
 SCD18p represents 18:1/18:0 in plasma phospholipids. 
Activity derived from Baecke Survey (32).  
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Figure 1: Hazard Ratios for association of SCD-1 quintiles with Incident Diabetes. 
Model 1: Adjusted for age and gender. Model 2: Additionally adjusted for other 
risk factors:  parental history of diabetes, cigarette smoking, mean arterial 
pressure, physical activity, dietary fiber intake, carbohydrate intake, saturated fat 
intake, alcohol use, education, waist-hip ratio and BMI.. Model 3: Model 2 
additionally adjusted for HOMA-IR. Quintile 1 (lowest level of SCD-1 ratio) is the 
common reference group. P trend measured the association between the linear 
relationship across quintile levels and incident diabetes. Statistical significance 
was set at p<0.05 for all analyses. 
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Table 2:  Mean Baseline Risk Factors by Extreme Quintiles of SCD16c  
Lowest quintile (n=556) Highest quintile (n=556) p
SCD16c (range) 0.08-0.17 0.3 -1.2
Age (years) 52.9 (0.2) 53.8 (0.2) 0.01
Gender (male) 60.4% 36.2% p<0.01
Education (<high school) 4.9% 5.9% p<0.01
Positive parental history of diabetes (%)
19.6% 23.2% 0.37
Positive history of smoking
54.7% 72.9% p<0.01
Cigarette years smoked
248.6 (15.2) 436.1 (18.0) p<0.01
Diet-fiber intake (grams) 17.4 (0.3) 15.2 (0.3) p<0.01
Diet-Carbohydrate (%kcal) 47.4 (0.3) 44.5 (0.4) p<0.01
Diet-Saturated fat (%kcal) 12.4 (0.1) 12.3 (0.1) 0.96
Alcohol intake (g/day) 3.8 (0.3) 16.9 (0.9) p<0.01
Total Activity [3 (low) to 15 (high)] 7.7 (0.1) 7.1 (0.1) p<0.01
Sport+Leisure Activity [2 (low) to 10 (high)] 5.4 (0.05) 4.9 (0.05) p<0.01
BMI (kg/m2) 25.4 (0.1) 27.3 (0.2) p<0.01
Waist hip Ratio 0.89 (0.004) 0.92 (0.003) p<0.01
Mean Arterial Pressure 85.6 (0.4) 90.2 (0.5) p<0.01
Fasting glucose (mmol/l) 5.4 (0.02) 5.6 (0.02) p<0.01
HOMA-IR 2.0 (0.1) 2.6 (0.1) p<0.01  
- Results reported as mean (Standard Error)  
SCD16c represents 16:1/16:0 in plasma cholesterol esters.  
Activity derived from Baecke Survey (32).  
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Table 3: Mean Baseline Risk Factors by Extreme Quintiles of SCD18p  
Lowest quintile (n=556) Highest quintile (n=556) p
SCD18p (range) 0.37-0.56 0.74-1.4
Age  (years) 53.7 (0.2) 53.2 (0.2) 0.09
Gender (male) 51.6% 45.1% 0.03
Education (<high school) 6.0% 6.3% 0.03
Positive parental history of diabetes (%) 22% 16% 0.07
Positive history of smoking 57% 70% p<0.01
Cigarette years smoked 268.6 (15.0) 406.8 (17.5) p<0.01
Diet-fiber intake (grams) 16.8 (0.3) 15 (0.3) p<0.01
Diet-Saturated fat (%kcal) 12.3 (0.1) 12.7 (0.1) 0.01
Diet-carbohydrate (%kcal) 47.1 (0.4) 44.7 (0.4) p<0.01
Alcohol intake (g/day) 4.9 (0.3) 14.6 (0.9) p<0.01
Total Activity [3 (low) to 15 (high)] 7.4 (0.1) 7.4 (0.1) 0.56
Sport+Leisure Activity [2 (low) to 10 (high)] 5.2 (0.1) 5.1 (0.1) 0.34
BMI (kg/m2) 27.7 (0.2) 25.1 (0.2) p<0.01
Waist hip Ratio 0.93 (0.003) 0.90 (0.004) p<0.01
Mean Arterial Pressure (mm Hg) 87.8 (0.4) 87.6 (0.5) 0.77
Fasting glucose (mg/dL) 5.6 (0.02) 5.4 (0.02) p<0.01
HOMA-IR 2.9 (0.1) 1.8 (0.1) p<0.01  
- Results reported as mean (Standard Error)  
SCD18p represents 18:1/18:0 in plasma phospholipids. 
Activity derived from Baecke Survey (32). 
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